Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSCT-MM16 induction, transplant, consolidation, and maintenance therapy for newly diagnosed multiple myeloma
jRCTs071180019Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide, dexamethasone, melphalan, carfilzomib and 2 more in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Complete response rate after consolidation therapy. Started Mar 2017; status: completed.
02
Drugs
bortezomiblenalidomidedexamethasonemelphalancarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs071180019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180019.